# HeartSciences (HSCS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HSCS
## Company Profile
- Ticker: HSCS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2 USD
- Market cap: 6592328.999999999 USD
- Last updated: 2026-08-12
## Business Overview
### AI-ECG Healthcare IT Company
HeartSciences is a healthcare information technology company focused on advancing ECG and EKG interpretation through artificial intelligence. Its MyoVista Insights platform is a device-agnostic ECG management system designed to improve clinical workflow, decision-making, and delivery of AI-ECG algorithms.
### MyoVista Commercial Transition
Fiscal 2026 marked the move of MyoVista Insights from development into commercial use. The company launched the platform, completed version upgrades, received Epic Toolbox designation and interoperability compliance, deployed with healthcare institutions, and launched its first AI-ECG algorithm on the platform.
### MyoVista wavECG Device
The MyoVista wavECG device is designed to provide conventional ECG functionality while supporting on-device AI-enabled solutions. HeartSciences submitted the device to the FDA for 510(k) premarket clearance in December 2025, and the submission remains under FDA review.
### Proposed Fortitude Transaction
HeartSciences is pursuing a business combination with Fortitude Mining Holdings, an institutional-scale Zcash mining platform owned by Digital Currency Group. If completed, the transaction would significantly change the company's profile by combining its AI-ECG business with a digital asset infrastructure business.
## Why The Stock Is Moving

As of Aug 12, 2026, HSCS closed down 2.44% at $2.00. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA review outcome for the MyoVista wavECG 510(k) submission.

## Recent News
- 2026-07-29 13:00 EST — [HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results](https://biopharmsignal.com/news/HSCS/heartsciences-files-preliminary-proxy-statement-for-business-combination-with-fo-565e47a4) — Source: HeartSciences
- 2026-07-23 21:15 EST — [HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K](https://biopharmsignal.com/news/HSCS/heartsciences-files-its-fiscal-2026-annual-report-on-form-10-k-51b4983b) — Source: HeartSciences
- 2026-06-11 12:30 EST — [European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents](https://biopharmsignal.com/news/HSCS/european-patent-granted-for-ecg-based-assessment-of-diastolic-function-expands-h-e7b16789) — Source: HeartSciences
- 2026-06-02 12:30 EST — [HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm](https://biopharmsignal.com/news/HSCS/heartsciences-launches-myovista-insights-version-1-3-with-ai-ecg-algorithm-marke-e814d01c) — Source: HeartSciences
- 2026-05-19 12:30 EST — [HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network](https://biopharmsignal.com/news/HSCS/heartsciences-signs-commercial-agreement-with-north-shore-health-the-first-hospi-a0d1b489) — Source: HeartSciences